Figure 2.
Disease-Free Survival After Treatment With mFOLFOX6 Alone and mFOLFOX6 With Cetuximab in the Wild-Type KRAS, Mutated KRAS, and Wild-Type KRAS and Mutated KRAS With Age <70 and ≥70 Years Patient Groups
mFOLFOX6 indicates the modified sixth version of the leucovorin, fluorouracil, and oxaliplatin regimen; HR, hazard ratio.